Newest GLP-1 Drugs: Retatrutide, Oral Options, and What's Next

The newest GLP-1 drugs in 2026 are retatrutide (an investigational triple GLP-1/GIP/glucagon agonist still in Phase 3 trials), orforglipron (an oral small-molecule pill that the FDA approved in April 2026 for chronic weight management), and CagriSema (a GLP-1 plus amylin combination that Novo Nordisk has filed for approval but the FDA has not yet cleared). Each is "newest" for a different reason: a new mechanism, a new route of delivery, or a new combination. The honest summary is that one is approved, two are not, and the headline weight-loss numbers, while striking, come from trials rather than years of real-world use.

This guide walks through what makes each of these new GLP-1 candidates different, where each one actually stands with regulators, and how that maps onto what you can realistically get today. We are careful with approval status throughout, because in this fast-moving area the difference between "approved" and "promising trial data" is the difference between a prescription and a press release.

What makes a GLP-1 drug one of the "newest"

The first generation of GLP-1 medicines, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), set a high bar, with mean weight loss of roughly 15% and 21% respectively in their pivotal trials. The newest GLP-1 drugs are trying to beat that bar in one of three ways. Some add a third hormone receptor to push weight loss higher. Some change the delivery from a weekly injection to a daily pill. Some pair a GLP-1 with a different appetite hormone entirely. Understanding which lever a given drug is pulling tells you most of what you need to know about it.

It helps to remember what this whole class is built on. These drugs are engineered versions of gut hormones that the body already uses to coordinate appetite and blood sugar, a story laid out in the complete guide to GLP-1 medications and in our explainer on the GLP-1 receptor agonist drug class. The newest agents are not a departure from that biology. They extend it.

The newest GLP-1 drugs at a glance

Here is where the leading new GLP-1 candidates stand as of mid-2026. Approval status changes, so treat this as a snapshot and confirm current labeling with a clinician or the manufacturer before acting on it.

Agent	Type / mechanism	Route	Status (mid-2026)
Retatrutide	Triple agonist: GLP-1 + GIP + glucagon	Weekly injection	Investigational, Phase 3 (not FDA-approved)
Orforglipron	Oral small-molecule GLP-1 agonist (non-peptide)	Daily pill	FDA-approved (April 2026) for chronic weight management
CagriSema	GLP-1 (semaglutide) + amylin analog (cagrilintide)	Weekly injection	Filed for FDA review, not yet approved
Tirzepatide (for reference)	Dual agonist: GLP-1 + GIP	Weekly injection	FDA-approved (Mounjaro / Zepbound)
Semaglutide (for reference)	GLP-1 agonist	Weekly injection / daily oral	FDA-approved (Ozempic / Wegovy / Rybelsus)

Retatrutide: the triple agonist pushing weight loss higher

Retatrutide is the new GLP-1 drug generating the most attention, and it is the reason the word "triple" keeps appearing in coverage of the pipeline. It activates three receptors at once: GLP-1 and GIP, the same two that tirzepatide engages, plus a third, the glucagon receptor. Adding glucagon is the conceptually new move. Glucagon raises blood sugar, which sounds counterproductive, but it also increases energy expenditure, so a carefully balanced triple agonist aims to suppress appetite and raise the number of calories burned at the same time. That combination targets both sides of the energy equation, which earlier drugs largely did not.

The trial numbers are large. In the Phase 3 TRIUMPH-1 study, the highest doses produced average weight loss in the high-20% range, with some longer-treatment analyses reaching roughly 30%, figures that approach what bariatric surgery achieves. Earlier Phase 2 data had shown about 24% average loss at 48 weeks.

The accuracy point that matters: retatrutide is not FDA-approved. It remains investigational, with the rest of its Phase 3 program (including trials in type 2 diabetes and in people with cardiovascular disease) still reporting out. You cannot get a legitimate retatrutide prescription for weight loss today, and any seller offering "retatrutide" outside a clinical trial is operating outside the regulated supply, which is a real safety risk. The reason glucagon is worth adding, and why activating multiple gut-hormone receptors outperforms GLP-1 alone, is unpacked in the difference between GLP-1 and GIP and in the analysis of how tirzepatide works as a dual agonist.

Orforglipron: the first oral small-molecule GLP-1 pill

If retatrutide is "newest" because of mechanism, orforglipron is "newest" because of how you take it. It is a small-molecule GLP-1 receptor agonist, which means it is not a peptide. That distinction is the whole point. Peptide drugs like semaglutide are fragile in the gut, which is why the existing oral semaglutide (Rybelsus) has very low absorption and must be taken on an empty stomach with strict timing. A small molecule is more stable, so orforglipron can be taken as a daily pill at any time of day, with no food or water restrictions.

Orforglipron is the new GLP-1 drug that has actually crossed the regulatory finish line. The FDA approved it in April 2026 for chronic weight management, on the strength of a large Phase 3 program. The weight-loss numbers are more modest than the injectable triple agonist, in the low-to-mid teens as a percentage at the higher doses, but the convenience of a pill is a genuine access change. Many people who would never start a weekly injection will start a daily tablet, and manufacturing pills at scale is easier than producing injectables, which matters for supply.

So orforglipron sits in a different category from the other two: it is available, not hypothetical. For context on why oral delivery has been such a long-standing goal of the field, and what it could mean for reach, see our look at the future of obesity science.

CagriSema: a GLP-1 paired with a second appetite hormone

CagriSema is the third new GLP-1 entrant, and it takes yet another approach. It combines semaglutide, the familiar GLP-1 agonist, with cagrilintide, an analog of amylin. Amylin is a separate hormone, co-secreted with insulin, that contributes to fullness and slows gastric emptying through its own pathway. The bet behind CagriSema is that hitting GLP-1 and amylin together produces more weight loss than either alone.

The trial results have been strong but, by the field's recent standards, slightly under the sky-high expectations that surrounded the drug, landing in roughly the low-20% range for weight loss. Novo Nordisk has filed CagriSema for FDA review, but it is not yet approved, so like retatrutide it is not something a clinician can prescribe for weight management today. It is worth watching precisely because amylin is a genuinely different mechanism from the GLP-1/GIP/glucagon family, which means it could help people who respond only partially to the current drugs.

How the newest GLP-1 drugs compare to what's available now

It is easy to read the pipeline numbers and conclude that everything on the market is now obsolete. That is not the right takeaway. The approved drugs, semaglutide and tirzepatide, have years of real-world safety data, established dosing, and a known side-effect profile. The newest GLP-1 drugs have impressive trial data and, in two of three cases, no approval at all. Bigger trial numbers are not the same as a better choice for any individual person.

Two caveats apply to every drug in this class, new or old. First, the weight loss happens while you are taking the medication; trials of stopping consistently show much of the lost weight returns, because the underlying appetite biology is unchanged. Second, the average hides wide variation, with some people responding strongly and a minority barely at all. Those realities do not disappear because a drug is newer. If you are weighing the two approved leaders against each other while the pipeline matures, our semaglutide versus tirzepatide comparison and the detailed Zepbound clinical trial results are the practical starting points.

What "approval status" actually means for you

This is the part that gets blurred in a lot of pipeline coverage, so it is worth being blunt. A drug with positive Phase 3 data is not a drug you can get. FDA approval is a separate, later step that reviews the full safety and efficacy package and sets the official dosing and labeling. Until that happens, the only legitimate way to receive an investigational agent like retatrutide or CagriSema is by enrolling in a clinical trial.

That distinction has a safety edge to it. Whenever a new GLP-1 drug makes headlines, unregulated sellers start marketing "research" versions of it, often the exact molecules that are not approved. The FDA has repeatedly warned about counterfeit and improperly compounded GLP-1 products with incorrect dosing and unverified ingredients. A vial labeled with the name of a Phase 3 drug, sold without a prescription, is not early access to the future. It is an unregulated product with no oversight. The safe path to any GLP-1 treatment runs through a licensed clinician and an approved medication or a credentialed pharmacy, never a checkout page selling a trial-stage compound.

How to access new GLP-1 treatment today

If you want the benefit of this class now rather than waiting for the next approval, the realistic options are the drugs that already cleared the FDA: semaglutide, tirzepatide, and, as of April 2026, the oral pill orforglipron. The good news is that access to these has become much more straightforward than it was even two years ago. Licensed telehealth providers can evaluate you, confirm whether a GLP-1 is medically appropriate, write a prescription if it is, and arrange delivery, all without an in-person clinic visit. For many people that online route removes the two biggest practical barriers, finding a willing prescriber and fitting in appointments.

The sensible sequence is to start a conversation with a qualified provider about the approved options, get an honest read on which fits your situation, and keep an eye on the pipeline for when retatrutide or CagriSema eventually clear review. A clinician who is already managing your treatment is also the right person to talk to about switching to a newer drug later, once it is genuinely available, rather than chasing it through unregulated channels in the meantime.

Key takeaways

• The newest GLP-1 drugs in 2026 are retatrutide, orforglipron, and CagriSema, each "new" for a different reason: mechanism, oral delivery, or a new combination.
• Retatrutide is a triple GLP-1/GIP/glucagon agonist with very high trial weight loss (high-20% range), but it is investigational and not FDA-approved.
• Orforglipron is the one that is actually approved: an oral small-molecule GLP-1 pill cleared by the FDA in April 2026 for chronic weight management.
• CagriSema pairs semaglutide with the amylin analog cagrilintide; it has been filed for FDA review but is not yet approved.
• Positive Phase 3 data is not the same as access. The only legitimate way to get an unapproved agent is a clinical trial; "research" versions sold online are an unregulated safety risk.
• To benefit from this class now, the approved drugs (semaglutide, tirzepatide, orforglipron) are the realistic route, available through a licensed clinician or telehealth provider.

The pipeline is moving fast, and the newest GLP-1 drugs may well reset expectations again over the next few years. If you want to act on what is proven and available today, the practical next step is a conversation with a licensed provider who can assess whether an approved GLP-1 medication fits your situation and arrange treatment if it does.